Boston Scientific is adding to its medsurg portfolio by acquiring a controlling interest in MI Tech, a Korean company that markets the Hanarostent line of nitinol stents for a variety of non-vascular indications.
Boston Scientific Adds More Non-Vascular Stents To MedSurg Business With MI Tech Acquisition
Boston Scientific will pay about $230m for 64% of Korea-based MI Tech, which developed the Hanarostent line of conformable, self-expanding metal stents for endoscopic and urologic applications.
